Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
8
×
Tags
biotech
boston blog main
8
×
eli lilly
8
×
life sciences
national blog main
boston top stories
clinical trials
fda
national top stories
indiana blog main
indiana top stories
san francisco blog main
san francisco top stories
raleigh-durham blog main
raleigh-durham top stories
amgen
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
genentech
national
new york blog main
new york top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
allergan
migraine research foundation
novartis
teva pharmaceutical
astrazeneca
avapritinib
avexis
What
fda
8
×
drug
approval
won
medicines
migraine
new
bio
blueprint
cancer
class
companies
decades
designed
drugs
news
regulatory
ret
roundup
treatment
acute
address
addresses
alkermes
amgen
antipsychotic
approved
approves
arguments
august
benefits
big
biotech
busy
candidate
candidates
carries
causes
caveats
certain
Language
unset
Current search:
photo
×
fda
×
" boston blog main "
×
" eli lilly "
×
@xconomy.com
3 years ago
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines